However, in another randomized, placebo-controlled study involving 120 patients with mild to moderate COVID-19, the subcutaneous administration of pegylated IFN-λ1 within 72 hours of diagnosis did not lead to a shorter duration of SARS-CoV-2 viral shedding nor did it result in symptom improvement (195). Here, IFNL1 is linked to COVID-19.